Monopar Therapeutics (MNPR) shareholders
Close on Nov 13, 2026Market cap $483.28MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC Joint filing with Janus Henderson Biotech Innovation Master Fund Ltd (16.70%) | 1,287,368 | 19.50% | 13G (passive) amendment | Sep 30, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 742,861 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 667,632 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| AstraZeneca PLC Joint filing with Alexion Pharmaceuticals, Inc. (7.80%) | 522,667 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (6.23%), Phillip Gross (6.23%) | 424,195 | 6.23% | 13G (passive) amendment | Mar 31, 2026 |
| Xiaoying Tian Joint filing with Saturn V Capital Management LP (5.20%) | 345,626 | 5.20% | 13G (passive) | Jan 5, 2026 |
| BlackRock, Inc. | 338,133 | 5.03% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,312,129 | 19.55% | $121.70M | New | 0.05% |
| Ra Capital Management, L.P. | 667,207 | 9.94% | $61.78M | – | 0.54% |
| BlackRock, Inc. | 348,819 | 5.20% | $32.30M | +32,252 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 323,745 | 4.82% | $29.98M | – | 0.31% |
| Saturn V Capital Management LP | 311,976 | 4.65% | $28.89M | −33,650 | 4.14% |
| Siren, L.L.C. | 270,118 | 4.02% | $25.01M | – | 0.51% |
| ADAR1 Capital Management, LLC | 217,595 | 3.24% | $20.15M | −46,683 | 0.92% |
| Polar Capital Holdings Plc | 214,469 | 3.20% | $19.86M | −12,057 | 0.05% |
| Vanguard Capital Management LLC | 209,711 | 3.12% | $19.42M | −8,752 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 209,195 | 3.12% | $19.37M | −100,000 | 0.03% |
| TCG Crossover Management, LLC | 203,327 | 3.03% | $18.83M | +71,224 | 0.45% |
| Wellington Management Group Llp | 158,437 | 2.36% | $14.67M | −15,905 | 0.00% |
| Orbimed Advisors LLC | 157,423 | 2.35% | $14.58M | New | 0.27% |
| Candriam S.C.A. | 143,339 | 2.14% | $13.26M | New | 0.06% |
| Balyasny Asset Management L.P. | 134,543 | 2.00% | $12.46M | −1,900 | 0.02% |
| Geode Capital Management, LLC | 112,578 | 1.68% | $10.43M | +12,660 | 0.00% |
| Alyeska Investment Group, L.P. | 100,000 | 1.49% | $9.26M | – | 0.02% |
| State Street Corp | 92,551 | 1.38% | $8.57M | +4,196 | 0.00% |
| Vivo Capital, LLC | 90,500 | 1.35% | $8.38M | – | 0.77% |
| Driehaus Capital Management LLC | 84,040 | 1.25% | $7.78M | +50,884 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 6M | 92.7% | 30 / 32 | 24 / 14 | 2M | 1M |
| Q1 2026 | 82 | 6M | 92.9% | 20 / 33 | 18 / 11 | 2M | 1M |
| Q4 2025 | 74 | 6M | 82.3% | 23 / 32 | 10 / 5 | 1M | 0M |
| Q3 2025 | 56 | 4M | 64.6% | 16 / 19 | 14 / 3 | 1M | 0M |
| Q2 2025 | 43 | 3M | 47.3% | 19 / 15 | 4 / 11 | 0M | 0M |
| Q1 2025 | 35 | 3M | 43.0% | 18 / 6 | 5 / 1 | 0M | 0M |
| Q4 2024 | 18 | 3M | 38.4% | 12 / 3 | 1 / 0 | 3M | 0M |
| Q3 2024 | 6 | 0M | 0.2% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
98 funds held MNPR in Q2 2026, 67% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MNPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 159,786 | 2.38% | $14.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 118,700 | 1.77% | $10.99M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 49,332 | 0.73% | $5.35M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 44,311 | 0.66% | $4.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 31,751 | 0.47% | $2.94M | 0.02% | Jun 30, 2026 |
| Neuberger Small Cap Growth Fund | 25,313 | 0.38% | $1.65M | 0.24% | May 31, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 23,890 | 0.36% | $2.21M | 0.25% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 22,728 | 0.34% | $1.48M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 20,497 | 0.31% | $1.33M | 0.00% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 19,767 | 0.29% | $1.29M | 0.07% | May 31, 2026 |
| iShares Micro-Cap ETF | 15,148 | 0.23% | $1.40M | 0.09% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 10,953 | 0.16% | $1.19M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 10,465 | 0.16% | $968.95K | 0.01% | Jun 30, 2026 |
| Master Small Cap Index Series | 7,737 | 0.12% | $716.37K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 7,192 | 0.11% | $467.77K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chandler Robinson | Chief Executive Officer, Director | 166,942 | 2.49% | Oct 20, 2026 |
| Pharma LLC Tactic | Chief Executive Officer, Director, 10% owner | 4,383,299 | 65.30% | Sep 26, 2025 |
| Quan Anh Vu | Chief Financial Officer | 2,655 | 0.04% | Oct 2, 2026 |
| Andrew Cittadine | Chief Operating Officer | 58,054 | 0.86% | Oct 2, 2026 |
| Susan Rodriguez | CCSO | – | – | Mar 4, 2026 |
| Kim R. Tsuchimoto | Director | 11,486 | 0.17% | Nov 4, 2026 |
| Raymond Anderson | Director | 5,373 | 0.08% | Nov 4, 2026 |
| Christopher M. Starr | Director | 15,053 | 0.22% | Oct 5, 2026 |
| Nicole Sweeny | Director | – | – | Jun 30, 2026 |
| Arthur J. Klausner | Director | 3,064,156 | 45.65% | Dec 19, 2025 |
| Lavina Talukdar | Director | 14,001 | 0.21% | Dec 8, 2025 |
| Patrice Rioux | – | 5,066 | 0.08% | Aug 27, 2026 |
| Diane Hendricks | 10% owner | 567,580 | 8.46% | Dec 17, 2025 |
| Thomas V. O'Halloran | – | 4,402,940 | 65.60% | Sep 26, 2025 |
| Andrew Paul Mazar | – | 188,792 | 2.81% | Sep 26, 2025 |
| Michael J. Brown | – | 4,933,528 | 73.50% | Sep 26, 2025 |
| LLC TacticGem | 10% owner | 0 | – | Dec 17, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kim R. Tsuchimoto Director | Nov 4, 2026 | Sale(10b5-1 plan) | −600 | $72.21 | $43.33K | 0 |
| Kim R. Tsuchimoto Director | Nov 4, 2026 | Sale(10b5-1 plan) | −996 | $71.35 | $71.06K | 600 |
| Kim R. Tsuchimoto Director | Nov 4, 2026 | Sale(10b5-1 plan) | −1,295 | $70.75 | $91.62K | 1,596 |
| Kim R. Tsuchimoto Director | Nov 4, 2026 | Option exercise | +2,035 | $14.00 | $28.49K | 2,891 |
| Kim R. Tsuchimoto Director | Nov 4, 2026 | Option exercise | +856 | $30.00 | $25.68K | 856 |
| Raymond Anderson Director | Nov 2, 2026 | Sale(10b5-1 plan) | −1,502 | $70.04 | $105.20K | 5,373 |
| Raymond Anderson Director | Nov 2, 2026 | Sale(10b5-1 plan) | −200 | $68.68 | $13.74K | 6,875 |
| Raymond Anderson Director | Nov 2, 2026 | Sale(10b5-1 plan) | −600 | $67.06 | $40.24K | 7,075 |
| Raymond Anderson Director | Nov 2, 2026 | Sale(10b5-1 plan) | −840 | $66.16 | $55.57K | 7,675 |
| Raymond Anderson Director | Nov 2, 2026 | Option exercise | +1,740 | $30.00 | $52.20K | 8,515 |
| Raymond Anderson Director | Nov 2, 2026 | Option exercise | +1,402 | $30.00 | $42.06K | 6,775 |
| Kim R. Tsuchimoto Director | Nov 2, 2026 | Sale(10b5-1 plan) | −1,199 | $70.10 | $84.05K | 0 |
| Kim R. Tsuchimoto Director | Nov 2, 2026 | Option exercise | +1,199 | $30.00 | $35.97K | 1,199 |
| Chandler Robinson Chief Executive Officer, Director | Oct 20, 2026 | Tax withholding | −597 | $92.59 | $55.28K | 104,127 |
| Christopher M. Starr Director | Oct 1, 2026 | Sale(10b5-1 plan) | −799 | $79.67 | $63.66K | 5,173 |
| Christopher M. Starr Director | Oct 1, 2026 | Sale(10b5-1 plan) | −2,970 | $78.82 | $234.10K | 5,972 |
| Christopher M. Starr Director | Oct 1, 2026 | Sale(10b5-1 plan) | −4,631 | $78.09 | $361.63K | 8,942 |
| Christopher M. Starr Director | Oct 1, 2026 | Option exercise | +8,400 | $0.01 | $42 | 13,573 |
| Andrew Cittadine Chief Operating Officer | Sep 30, 2026 | Tax withholding | −1,944 | $79.67 | $154.88K | 58,054 |
| Andrew Cittadine Chief Operating Officer | Sep 30, 2026 | Option exercise | +4,384 | – | – | 59,998 |
| Chandler Robinson Chief Executive Officer, Director | Sep 30, 2026 | Tax withholding | −4,344 | $79.67 | $346.09K | 104,724 |
| Chandler Robinson Chief Executive Officer, Director | Sep 30, 2026 | Option exercise | +9,801 | – | – | 109,068 |
| Quan Anh Vu Chief Financial Officer | Sep 30, 2026 | Tax withholding | −180 | $79.67 | $14.34K | 2,655 |
| Quan Anh Vu Chief Financial Officer | Sep 30, 2026 | Option exercise | +614 | – | – | 2,835 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +15,000 | $14.00 | $210.00K | 128,323 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +14,056 | $30.00 | $421.68K | 113,323 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −10,450 | $87.15 | $910.72K | 117,873 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −9,638 | $87.96 | $847.76K | 108,235 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −8,368 | $88.97 | $744.50K | 99,867 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −600 | $89.79 | $53.87K | 99,267 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −1,098 | $111.84 | $122.80K | 1,192 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Option exercise | +2,055 | $30.00 | $61.65K | 2,055 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Option exercise | +2,035 | $14.00 | $28.49K | 4,090 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −485 | $108.83 | $52.78K | 3,605 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −615 | $109.56 | $67.38K | 2,990 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −590 | $113.84 | $67.17K | 0 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −602 | $112.93 | $67.98K | 590 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −700 | $110.65 | $77.46K | 2,290 |
| Patrice Rioux – | Aug 26, 2026 | Option exercise | +1,380 | $0.01 | $14 | 5,066 |
| Patrice Rioux – | Aug 26, 2026 | Sale(10b5-1 plan) | −1 | $111.26 | $111 | 5,065 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −485 | $108.83 | $52.78K | 11,001 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −590 | $113.84 | $67.17K | 7,396 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −615 | $109.56 | $67.38K | 10,386 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −700 | $110.65 | $77.46K | 9,686 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −1,098 | $111.84 | $122.80K | 8,588 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −602 | $112.93 | $67.98K | 7,986 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −1,802 | $113.05 | $203.72K | 5,373 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −694 | $110.04 | $76.37K | 7,821 |
| Raymond Anderson Director | Aug 25, 2026 | Option exercise | +1,740 | $30.00 | $52.20K | 8,515 |
| Raymond Anderson Director | Aug 25, 2026 | Option exercise | +1,402 | $30.00 | $42.06K | 6,775 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −646 | $111.07 | $71.75K | 7,175 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −1,802 | $113.05 | $203.72K | 23,751 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −646 | $110.07 | $71.11K | 25,523 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −694 | $110.04 | $76.37K | 26,169 |
| Andrew Cittadine Chief Operating Officer | Jun 30, 2026 | Option exercise | +5,254 | – | – | 57,923 |
| Andrew Cittadine Chief Operating Officer | Jun 30, 2026 | Tax withholding | −2,309 | $92.59 | $213.79K | 55,614 |
| Quan Anh Vu Chief Financial Officer | Jun 30, 2026 | Tax withholding | −507 | $92.59 | $46.94K | 2,221 |
| Quan Anh Vu Chief Financial Officer | Jun 30, 2026 | Option exercise | +1,228 | – | – | 2,728 |
| Chandler Robinson Chief Executive Officer, Director | Jun 30, 2026 | Tax withholding | −4,084 | $92.59 | $378.14K | 99,267 |
| Chandler Robinson Chief Executive Officer, Director | Jun 30, 2026 | Option exercise | +12,873 | – | – | 103,351 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Monopar Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,507 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher M. Starr Director | Oct 1, 2026 | 16,800 | $1.34M | Oct 1, 2026 | Exercise of Stock Options |
| Chandler Robinson Director, Officer | Sep 24, 2026 | 29,056 | $2.60M | Sep 24, 2026 | Exercise of Stock Options |
| Patrice Rioux Acting Chief Medical Officer | Aug 26, 2026 | 1 | $111 | Aug 26, 2026 | Exercise of Stock Options |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | 8,180 | $906.51K | Aug 26, 2026 | Exercise of Stock Options |
| Raymond Anderson Director | Aug 25, 2026 | 6,284 | $699.79K | Aug 25, 2026 | Exercise of Stock Options |
| Arthur J. Klausner Former Board Member | Jul 10, 2026 | 5,000 | $476.97K | Jul 8, 2026 | Restricted Stock Unit Vesting |
| Arthur J. Klausner Employer | Jul 7, 2026 | 5,000 | $485.25K | Jul 7, 2026 | LP in LLC |
| Arthur J. Klausner Board Member | Dec 19, 2025 | 5,121 | $343.90K | Dec 18, 2025 | LP in LLC |
| Kim R. Tsuchimoto Director | Jul 14, 2025 | 8,904 | $356.16K | Jul 14, 2025 | Stock Option Exercise |
| Chandler Robinson Officer, Director | Jul 14, 2025 | 16,800 | $672.00K | Jul 14, 2025 | Stock Option Exercise |
| Christopher M. Starr Director | Jul 14, 2025 | 16,800 | $672.00K | Jul 14, 2025 | Stock Option Exercise |
| Pharma LLC Tactic 10% Stockholder | Apr 2, 2025 | 33,334 | $1.17M | Apr 2, 2025 | Private Placement |
See a number that looks wrong?